Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Multi-targeted approach in the treatment of thyroid cancer

Authors Scott N Pinchot, Rebecca S Sippel, Herbert Chen

Published Date August 2008 Volume 2008:4(5) Pages 935—947

DOI http://dx.doi.org/10.2147/TCRM.S3062

Published 4 August 2008

Scott N Pinchot, Rebecca S Sippel, Herbert Chen1

1Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin Madison, Wisconsin, USA

Abstract: While accounting for only 1% of solid organ malignancies (9% in women), thyroid carcinoma is the most common malignancy of the endocrine system. Although most patients have a favorable prognosis, over 1,500 people will die from thyroid carcinoma each year. The spectrum of disease types range from papillary thyroid cancer, which is a well-differentiated indolent tumor, to anaplastic carcinoma, a poorly differentiated fulminant cancer. With advances in diagnostic methods, surgical techniques, and clinical care of patients with thyroid carcinoma, the current management of thyroid cancer demands a multidisciplinary approach. The majority of patients with well-differentiated thyroid carcinoma of follicular cell origin are cured with adequate surgical management; however, some thyroid malignancies such as medullary thyroid carcinoma (MTC) or poorly differentiated thyroid carcinomas frequently metastasize, precluding patients from a curative resection. As such, novel palliative and therapeutic strategies are needed for this patient population. Here, we explore the current management of thyroid carcinoma, including surgical management of the primary tumor, lymph node disease, and locoregional recurrence. Likewise, we explore the application of current molecular techniques, reviewing nearly two decades of data that have begun to elucidate critical genetic pathways and therapeutic drug targets which may be important in specific thyroid tumor types.

Keywords: thyroid carcinoma; vascular endothelial growth factor receptor (VEGFR); epidermal growth factor receptor (EGFR); RET tyrosine kinase (RTK); glycogen synthase kinase-3β (GSK-3β)

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Depressive symptoms in caregivers of patients with dementia: demographic variables and burden

De Fazio P, Ciambrone P, Cerminara G, Barbuto E, Bruni A, Gentile P, Talarico A, Lacava R, Gareri P, Segura-Garcia C

Clinical Interventions in Aging 2015, 10:1085-1090

Published Date: 1 July 2015

Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes

Brott DA, Furlong ST, Adler SH, Hainer JW, Arani RB, Pinches M, Rossing P, Chaturvedi N

Drug Design, Development and Therapy 2015, 9:3191-3198

Published Date: 22 June 2015

“I am active”: effects of a program to promote active aging

Mendoza-Ruvalcaba NM, Arias-Merino ED

Clinical Interventions in Aging 2015, 10:829-837

Published Date: 5 May 2015

The impact of hearing loss on language performance in older adults with different stages of cognitive function

Lodeiro-Fernández L, Lorenzo-López L, Maseda A, Núñez-Naveira L, Rodríguez-Villamil JL, Millán-Calenti JC

Clinical Interventions in Aging 2015, 10:695-702

Published Date: 9 April 2015

Development of an oral push–pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles

Zhao Z, Wu C, Zhao Y, Hao Y, Liu Y, Zhao W

International Journal of Nanomedicine 2015, 10:1691-1701

Published Date: 3 March 2015

Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy

Zhuang B, Li Z, Pang J, Li W, Huang P, Wang J, Zhou Y, Lin Q, Zhou Q, Ye X, Ye H, Liu Y, Zhang LM, Chen R

International Journal of Nanomedicine 2015, 10:939-947

Published Date: 29 January 2015

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

Ross KA, Loyd H, Wu W, Huntimer L, Ahmed S, Sambol A, Broderick S, Flickinger Z, Rajan K, Bronich T, Mallapragada S, Wannemuehler MJ, Carpenter S, Narasimhan B

International Journal of Nanomedicine 2015, 10:229-243

Published Date: 30 December 2014

Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine

Chen J, Yan GJ, Hu RR, Gu QW, Chen ML, Gu W, Chen ZP, Cai BC

International Journal of Nanomedicine 2012, 7:3567-3577

Published Date: 26 July 2012